Seminars in Nuclear Medicine
Volume 40, Issue 4 , Pages 220-241 , July 2010

Altered Biodistribution of Radiopharmaceuticals: Role of Radiochemical/Pharmaceutical Purity, Physiological, and Pharmacologic Factors

  • Shankar Vallabhajosula, PhD

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Shankar Vallabhajosula, Professor of Radiochemistry and Radiopharmacy, Department of Radiology, Weill Cornell Medical College of Cornell University, 525 East 68th Street, Nuclear Medicine, STARR-221, New York, NY 10065
    • ,
  • Ronan P. Killeen, MD
    • ,
  • Joseph R. Osborne, MD, PhD

References 

  1. Hladik WB, Norenberg JP. Problems associated with the clinical use of radiopharma-ceuticals: A proposed classification system and trouble shooting guide. Eur J Nucl Med. 1996;23:997–1002
  2. Lentle BC, Scott JR, Noujaim AA, et al. latrogenic alterations in radionuclide biodistributions. Semin Nucl Med. 1979;9:131–143
  3. Hung JC, Pronto JA, Hammers RJ. Radiopharmaceutical-related pitfalls and artifacts (Semi). Nucl Med. 1996;26:208–255
  4. Hojelse C, Kristensen K, Sampson CB. Factors which affect the integrity of radiopharmaceuticals. In:  Sampson CB editors. Textbook of Radiopharmacy, Theory and Practice (ed 2). Amsterdam: Gordon and Breach Science Publishers; 1994;p. 145–152
  5. Hladik WB, Nigg NK, Rhodes BA. Drug induced changes in the biologic distribution of radiopharmaceuticals. Semin Nucl Med. 1982;12:184–218
  6. Hesselewood S, Leung E. Drug interactions with radiopharmaceuticals. Eur J Nucl Med. 1994;21:348–356
  7. Sampson CB. Adverse reactions and drug interactions with radiopharmaceuticals. Drug Saf. 1993;8:280–294
  8. Leung E, Hesslewood S. Use of non-radioactive drugs in nuclear medicine. Pharm J. 1992;249:HS32–HS36
  9. Saha GB. Adverse reactions to and altered biodistribution of radiopharmaceuticals. In:  Saha GB editors. Fundamentals of Nuclear Pharmacy (ed 4). New York: Springer; 2004;p. 351–353
  10. Chamarthy M, Travin MI. Altered biodistribution and incidental findings on myocardial perfusion imaging. Semin Nucl Med. 2010;40:257–270
  11. Zuckier LS, Freeman LM. Nonosseous, nonurologic uptake on bone scintigraphy: atlas and analysis. Semin Nucl Med. 2010;40:242–256
  12. Cohade C. Altered biodistribution on FDG-PET with emphasis on brown fat and insulin effect. Semin Nucl Med. 2010;40:283–293
  13. Liu Y, Ghesani NV, Zuckier LS. Physiology and pathophysiology of incidental findings detected on FDG-PET scintigraphy. Semin Nucl Med. 2010;40:294–315
  14. Shapiro B, Rufini V, Janwan A, et al. Artifacts, anatomic and physiological variants, and unrelated diseases that might cause false-positive whole-body 131-I Scans in patients with thyroid cancer. Semin Nucl Med. 2000;30:115–315
  15. Love C, Palestro CJ. Altered biodistribution and incidental findings on gallium and labeled leukocyte/bone marrow scans. Semin Nucl Med. 2010;40:271–282
  16. Vallabhajosula S. Molecular Imaging: Radiopharmaceuticals for PET and SPECT (ed 1). Berlin: Springer; 2009;
  17. Deutsch E, Libson K, Jurisson S, et al. Technetium chemistry and technetium radiopharmaceuticals. Prog Inorg Chem. 1983;30:75–139
  18. Nosco DL, Wolfangel RG, Bushman MJ, et al. Technetium-99m MAG3: Labeling conditions and quality control. J Nucl Med Technol. 1993;121:69–74
  19. Morrissey GJ, Powe JE. Microwave preparation of technetium-99m sulfur colloid. J Nucl Med Technol. 1992;20:159–162
  20. Henkin RE, Woodruff A, Chang W, et al. The effect of radiopharmaceutical incubation time on bone scan quality. Radiology. 1980;135:463–466
  21. Russell CD, Rowell K, Scott JW. Quality control of technetium-99m DTPA: Correlation of analytic tests with in vivo protein binding in man. J Nucl Med. 1986;27:560–562
  22. McBride MHD, Shaw SM, Kessler WV. Deterioration of stannous 1on in radiopharmaceutical kits during storage. Am J Hosp Pharm. 1979;36:1370–1372
  23. Owunwanne A, Church LB, Blau M. Effect of oxygen on the reduction of pertechnetate by stannous ion. J Nucl Med. 1977;18:822–826
  24. Bavne VJ, Forster AM, Tyrrell DA. Use of sodium iodide to overcome the eluate age restriction for Ceretec® reconstitution. Nucl Med Commun. 1989;10:29–33
  25. Kobayashi H, Suzuki KH, Sakahara H, et al. Oxygen bubbling can improve the labeling of pentavalent technetium-99m dimercaptosuccinic acid. Eur J Nucl Med. 1995;22:559–562
  26. Green JM, Donohoe ME, Foster ME, et al. Thin layer chromatographic procedures for the characterization of technetium-99m bicisate. J Nucl Med Technol. 1994;22:21–26
  27. Study KT, Hladik WB, Saha GB. Effects of Al+3 ion on 99mTc sulfur colloid preparations with different buffers. J Nucl Med Technol. 1984;12:16–18
  28. Jovanovi V, Jovanovic MS, Maksin T. Effect of aluminum on the radiochemical purity and 99mTc-MDP biodistribution. J Radioanal Nucl Chem Artic. 1988;122:57–63
  29. Wener RE, Thakur ML. Chemistry of gallium and indium radiopharmaceuticals. In:  Welch MJ,  Redvanly CS editor. Handbook of Radiopharmaceuticals. West Sussex, England: John Wiley & Sons; 2003;
  30. Vallabhajosula S, Harwig JF, Siemsen JK, et al. Radiogallium localization in tumors: Blood binding and transport and the role of transferrin. J Nucl Med. 1980;21:650–656
  31. Hoffer P. Gallium: Mechanisms. J Nucl Med. 1980;21:282–285
  32. Weiner RE. The mechanism of 67Ga localization in malignant disease. Nucl Med Biol. 1996;23:745–751
  33. Breeman WAP, Marion J, Visser TJ, et al. Optimising conditions for radiolabelling of DOTA-peptides with 90Y, 111In and 177Lu at high specific activities. Eur J Nucl Med Mol Imaging. 2003;33:917–920
  34. Steffel FG, Rao S. Rapid and simple methods for labeling white blood cells and platelets with indium-111 oxine. J Nucl Med Technol. 1987;15:61–65
  35. McAfee JG, Gagne GM, Subramanian G, et al. Distribution of leukocytes labeled with In-llloxine in dogs with acute inflammatory lesions. J Nucl Med. 1980;21:1059–1068
  36. Hunter VW, Kulkarni MV, Price R. Thallous vs thallic TI-201: Factors influencing biodistribution and myocardial turnover. J Nucl Med. 1981;22:82;(abstr)
  37. Dadachova E, Carrasco N. The Na+/I− symporter (NIS): Imaging and therapeutic applications. Semin Nucl Med. 2004;34:23–31
  38. Sternthal E, Lipworth L, Stanley B, et al. Suppression of thyroid radioiodine uptake by various doses of stable iodine. N Engl J Med. 1980;303:1083–1088
  39. Oswald WM, Hung JC, Gross GP. A study to measure the volatility of liquid 1-131 for clinical applications. J Nucl Med Technol. 1994;122:123
  40. Yu M-D, Huang W-S, Cherng C-C, et al. The effect of formulation on reduced radioiodide thyroid uptake. J Nucl Med. 2002;43:56–60
  41. Rini JN, Vallabhajosula S, Zanzonico P, et al. Thyroid uptake of liquid versus capsule 131I tracers in hyperthyroid patients treated with liquid 131I. Thyroidology. 1999;9:347–352
  42. Wafelman AR, Hoefnagel CA, Beijnen JH. Radiochemical stability during infusion of 131I-labeled metaiodobenzylguanidine for therapeutic use. Nucl Med Commun. 1993;14:819–822
  43. Vallabhajosula S. 18F-labeled positron emission tomographic radiopharmaceuticals in oncology: An overview of radiochemistry and mechanisms of tumor localization. Semin Nucl Med. 2007;37:400–419
  44. Ongseng F, Goldfarb CR, Finestone H. Axillary lymph node uptake of technetium-99m-MDP. J Nucl Med. 1995;36:1797–1799
  45. Hoop B. The infiltrated radiopharmaceutical injection: Risk considerations. J Nucl Med. 1991;32:890–891
  46. Piers DA, Beekhuis H. Local radiation dose from extravascular T1-201. J Nucl Med. 1987;28:684;(abstr)
  47. Goldberg E, Lieberman C. “Hot spots” in lung scans. J Nucl Med. 1977;18:499
  48. Gentili A, Miron SD, Adler LP. Review of some common artifacts in nuclear medicine. Clin Nucl Med. 1994;19:138–143
  49. Fisher SM, Brown RG, Greyson ND. Unbinding of 99mTc by iodinated antiseptics. J Nucl Med 18:1139-1140; 1977;(letter)
  50. Peterson EM, Ryan JW, Martin WB. Gastric activity on Tc-99m oxidronate bone scans can be caused by isopropyl alcohol. J Nucl Med. 1986;27:1090;(abstr)
  51. Gnanasegaran G, Cook G, Adamson K, et al. Patterns, variants, artifacts, and pitfalls in conventional radionuclide bone imaging and SPECT/CT. Semin Nucl Med. 2009;39:380–395
  52. Ergün ELKiratli PÖ, Günay EC, et al. A report on the incidence of intestinal 99mTc-methylene diphosphonate uptake of bone scans and a review of the literature. Nucl Med Commun. 2006;27:877–885
  53. Loutfi I, Collier BD, Mohammed AM. Nonosseous abnormalities on bone scans. J Nucl Med Technol. 2003;31:149–153
  54. Griffeth LK. Use of PET/CT scanning in cancer patients: Technical and practical considerations. Proc (Bayl Univ Med Cent). 2005;18:321–330
  55. Cook GJR, Fogelman I, Maisey MN. Normal physiological and benign pathological variants of 18-fluoro-2-deoxyglucose positron-emission tomography scanning: Potential for error in interpretation. Semin Nucl Med. 1996;26:308–314
  56. Tu D-G, Yao W-J, Chang T-W, et al. Flare phenomenon in positron emission tomography in a case of breast cancer-a pitfall of positron emission tomography imaging interpretation. Clin Imaging. 2009;33:468–470
  57. Abouzied MM, Crawford ES, Nabi HA. 18F-FDG imaging: Pitfalls and artifacts. J Nucl Med Technol. 2005;33:145–155
  58. Kostakoglu L, Hardoff R, Mirtcheva R, et al. PET-CT fusion imaging in differentiating physiologic from pathologic FDG uptake. Radiographics. 2004;24:1411–1431
  59. Lindholm P, Minn H, Leskinen-Kallio S. Influence of the blood glucose concentration on FDG uptake in cancer: A PET study. J Nucl Med. 1993;34:1–6
  60. Roy FN, Beaulieu S, Boucher L, et al. Impact of intravenous insulin on 18F-FDG PET in diabetic cancer patients. J Nucl Med. 2009;50:178–183
  61. Liu Y. Benign ovarian and endometrial uptake on FDG-PET/CT. Ann Nucl Med. 2009;23:107–112
  62. Schelbert HR. Positron emission tomography of the heart: Methodology, findings in the normal and disease heart, and clinical applications. In:  Phelps ME editors. PET: Molecular Imaging and Its Clinical Applications. New York: Springer; 2004;
  63. Kailasnath P, Sinusas AJ: Comparison of Tl-201, with Tc-99m labeled myocardial perfusion agents: Technical physiologic and clinical issues. J Nucl Cardiol 8:482-498
  64. Fukumoto M. Single-photon agents for tumor imaging: 201Tl, 99mTc-MIBI, and 99mTc-tetroformin. Ann Nucl Med. 2004;18:79–95
  65. Morris LF, Waman AD, Braunstein GD. Thyroid stunning. Thyroidology. 2003;13:333–340
  66. Shapiro B, Rufini V, Jarvan A, et al. Artifacts, anatomical, and physiological variants, and unrelated diseases that might cause false-positive whole-body 131I scans in patients with thyroid cancer. Semin Nucl Med. 2000;30:115–132
  67. Smith JR, Oates E. Radionuclide imaging of the thyroid gland: Patterns, pearls and pitfalls. Clin Nucl Med. 2004;29:181–193
  68. Goldsmith SJ, Vallabhajosula S. Clinically proven radiopharmaceuticals for infection imaging: Mechanisms and applications. Semin Nucl Med. 2009;39:2–10
  69. Rufini V, Calcagni ML, Baum RP. Imaging of neuroendocrine tumors. Semin Nucl Med. 2006;36:228–247
  70. Agostini D, Verberne HJ, Hamon A, et al. Cardiac 123I-mIBG scintigraphy in heart failure. Q J Nucl Med Mol Imaging. 2008;52:369–377
  71. Nakajima K, Yoshita M, Matsuo S, et al. Iodine-123 mIBG sympathetic imaging in Lewy body diseases and related movement disorders. Q J Nucl Med Mol Imaging. 2008;52:378–387
  72. Iwasa K, Nakajima K, Yoshikawa H, et al. Decreased myocardial 1231-mIBG uptake in Parkinson's disease. Acta Neurol Scand. 1998;97:303–306
  73. Taneja SS. ProstaScint scan: Contemporary use in clinical practice. Rev Urol. 2004;6(suppl 10):S19–S28
  74. Fink-Bennett DM, Thomas K. 90Y-ibritumomab tiuxetan in the treatment of relapsed or refractory B-cell non-Hodgkin's lymphoma. J Nucl Med Technol. 2003;31:61–68
  75. Goldsmith SJ. Radioimmunotherapy of lymphoma: Bexxar and Zevalin. Semin Nucl Med. 2010;40:122–135
  76. Conti PS, White C, Pieslor P, et al. The role of imaging with 111In-ibritumomab tiuxetan in the ibritumomab tiuxetan (Zevalin) regimen: Results from a Zevalin Imaging Registry. J Nucl Med. 2005;46:1812–1818
  77. Sampson CB, Cox PH. Effect of patient medication and other factors on the biodistribution of radiopharmaceuticals. In:  Sampson CB editors. Texbook of Radiopharmacy, Theory and Practice (ed 2). Amsterdam: Gordon and Breach Science Publishers; 1994;p. 215–227
  78. Morrison RT, Steuart RD. Delayed massive soft tissue uptake of Tc-99m MDP after radiation therapy for cancer of the breast. Clin Nucl Med. 1995;20:770–771
  79. Mankoff DA, Dunnwald LK, Gralow JR, et al. Changes in blood flow and metabolism in locally advanced breast cancer treated with neoadjuvant chemotherapy. J Nucl Med. 2003;44:1806–1814
  80. Dehadashi F, Flanagan FL, Mortimer JE, et al. Positron emission tomography assessment of “metabolic flare” to predict response of metastatic breast cancer to antiestrogen therapy. Eur J Nucl Med. 1999;26:51–56
  81. Zaplatnikov K, Menzel C, Dobert N, et al. Drug interference with mIBG uptake in a patient with metastatic paraganglioma. Br J Radiol. 2004;77:525–527

PII: S0001-2998(10)00015-2

doi: 10.1053/j.semnuclmed.2010.02.004

Seminars in Nuclear Medicine
Volume 40, Issue 4 , Pages 220-241 , July 2010

Article Tools

* Image Usage & Resolution